What I was working to say, Mr. Chair, is we have a variety of tools available now. We continue to look at other strategies, including essential medicines that we established during the pandemic—as has been transparently documented, a critical drug reserve—and we are learning the lessons from that as we consider it going forward.
On November 15th, 2022. See this statement in context.